Study Links Glucosamine Supplement to Faster Alzheimer's Progression in People with Mild Cognitive Impairment
Researchers at the University of Florida found that people with mild cognitive impairment who took glucosamine were 25% more likely to progress to dementia, and glucosamine users with Alzheimer's disease showed a 25% increase in mortality risk. The study analyzed health records from over 4,600 patients combined with brain imaging and mouse models, published in Nature Metabolism. The findings suggest glucosamine may interfere with metabolic processes already disrupted in Alzheimer's disease, though researchers emphasize the results do not prove causation and require confirmation through clinical trials.
University of Florida researchers conducted a large-scale analysis of deidentified patient health records from 2012 to 2024, examining over 4,600 patients with Alzheimer's disease or mild cognitive impairment, of whom approximately 8% reported taking glucosamine supplements. The study found that glucosamine use was associated with a 25% greater likelihood of MCI patients developing dementia and a 25% increase in mortality risk among those already diagnosed with Alzheimer's disease. The researchers used artificial intelligence to analyze the data while controlling for age, sex, and demographic factors, and supplemented this with advanced spatial imaging of human brain tissue and mouse models to identify a potential biological mechanism. The work points to a protein and sugar-tagging metabolic pathway that appears excessively active in Alzheimer's disease and may be influenced by glucosamine, which is a sugar-related molecule capable of crossing the blood-brain barrier. While the findings suggest altered metabolism plays a significant role in Alzheimer's progression, the researchers acknowledge that the results do not establish causation and will require confirmation through clinical trials before definitive conclusions can be drawn.
What's missing
The study's limitations include its observational design based on health records, which cannot establish causation; potential confounding variables not captured in the analysis; the possibility of reverse causation (people with early cognitive decline may have increased joint pain and thus higher glucosamine use); and lack of information on glucosamine dosage, duration of use, or specific formulations used by patients. The researchers note that findings require confirmation in prospective clinical trials before clinical recommendations can be made.
What different sources said
- Science DailyCenter
Popular joint supplement glucosamine linked to faster Alzheimer’s progression
Related
Australia's TGA Launches Major Crackdown on Illegal Peptides Amid Surge in Use
Australia's Therapeutic Goods Administration (TGA) has escalated enforcement against unregulated peptides, designating them a priority focus area alongside weight loss medications and vapes. The move responds to explosive growth in illegal peptide imports and supply driven by social media influencers promoting unproven health and beauty benefits. The crackdown reflects emerging safety concerns, including severe allergic reactions and hospitalizations, with authorities warning of potential product seizures and criminal penalties.
Mounjaro Misuse Surge in Japan Prompts Police Action and Health Ministry Warning
Osaka police referred three people to prosecutors for illegally selling Mounjaro, a diabetes drug used off-label for weight loss, without authorization. The incident reflects growing demand among Japanese women, some of whom are already medically underweight, driven by cultural beauty standards emphasizing thinness. Health authorities are increasing surveillance of social media to combat illegal distribution and address health risks from unauthorized use.
Newsweek Releases 2027 Survey of America's Best Home Health Agencies
Newsweek and Statista have launched their second annual survey to identify and rank America's best home health agencies for 2027. The home health care industry has grown significantly, reaching $153.7 billion in recent revenue, as it allows patients to receive care while remaining in their homes. The survey aims to help patients and families identify quality providers in this rapidly expanding sector.